Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial-Reference-Cited by-同舟云学术

Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial

Published:2009-01 Issue:8 Volume:50 Page:1336-1344
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Raza Azra,Jurcic Joseph G.,Roboz Gail J.,Maris Michael,Stephenson Joseph J.,Wood Brent L.,Feldman Eric J.,Galili Naomi,Grove Laurie E.,Drachman Jonathan G.,Sievers Eric L.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10428190903050013

Reference22 articles.

1. Treatment of acute nonlymphocytic leukemia: use of anthracycline- cytosine arabinoside induction therapy and comparison of two maintenance regimens

2. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

3. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells

4. Heterogeneity of clonogenic cells in acute myeloblastic leukemia.

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab;Clinical Cancer Research;2022-03-03

2. Gemtuzumab ozogamicin (GO) as monotherapy and in combination with hypomethylation agents in the treatment of acute myeloid leukemia: a systematic meta-analysis;Hematology;2022-02-27

3. Immunotherapy for Acute Myeloid Leukemia: Allogeneic hematopoietic cell transplantation is here to stay;Leukemia Research;2022-01

4. A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia;Haematologica;2021-12-02

5. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design;Journal for ImmunoTherapy of Cancer;2021-09